galantamine hydrobromide / Generic mfg. |
NCT00297414: An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine |
|
|
| Completed | N/A | 1083 | US, Canada, Europe, RoW | No intervention | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Mild Cognitive Impairment | 01/05 | 01/05 | | |
NCT00297362: A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease |
|
|
| Completed | N/A | 344 | Europe | Galantamine hydrobromide | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Alzheimer Disease | | 10/05 | | |
NCT01734395: A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease |
|
|
| Completed | N/A | 1882 | RoW | Galantamine, Razadyne, Reminyl | Janssen Korea, Ltd., Korea | Alzheimer's Disease | 01/08 | 01/08 | | |
NCT00299676: An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period |
|
|
| Completed | N/A | 61 | RoW | Galantamine (Reminyl) | Janssen-Cilag Pty Ltd | Alzheimer Disease, Dementia, Galantamine | 03/08 | 03/08 | | |
NCT01009476: Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine |
|
|
| Completed | N/A | 1134 | Europe | Galantamine, Nootropics (ginkgo biloba, nicergoline, piracetam, or others) | Janssen-Cilag G.m.b.H | Dementia, Alzheimer Disease, Dementia, Vascular | 08/08 | 08/08 | | |
NCT01029132: Characteristics of Treatment Responders to Galantamine |
|
|
| Completed | N/A | 66 | RoW | galantamine, galantamine-reminyl | Samsung Medical Center, Janssen Korea, Ltd., Korea | Dementia | 10/09 | 10/09 | | |
| Terminated | N/A | 200 | US | Donepezil, Aricept, Galantamine, Razadyne, Rivastigmine, Exelon | Indiana University, Agency for Healthcare Research and Quality (AHRQ) | Dementia, Alzheimer's Disease | 10/15 | 10/15 | | |
NCT01944436: A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease |
|
|
| Completed | N/A | 57 | Canada | Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine) | Sunnybrook Health Sciences Centre | Lewy Body Disease | 01/16 | 01/16 | | |